Omeros Corporation (NASDAQ: OMER)
$5.10
+0.6550 ( +14.75% ) 467.7K
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Market Data
Open
$5.10
Previous close
$4.44
Volume
467.7K
Market cap
$295.23M
Day range
$4.38 - $5.10
52 week range
$0.92 - $5.84
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 75 | May 15, 2024 |
8-k | 8K-related | 16 | May 15, 2024 |
def | Proxies and info statements | 14 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 29, 2024 |
4 | Insider transactions | 1 | Apr 29, 2024 |
ars | Annual reports | 1 | Apr 29, 2024 |
10-k | Annual reports | 96 | Apr 01, 2024 |
8-k | 8K-related | 16 | Apr 01, 2024 |
8-k | 8K-related | 15 | Feb 07, 2024 |